IP Library Patent Application 18426803
Patent Application
App. No. 18/426,803

SELECTIVE CELL TARGETING USING ADENOVIRUS AND CHEMICAL DIMERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/426,803
Abstract

Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.

Claims (36)

1 . A recombinant nucleic acid encoding a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral capsid protein and a dimerizing agent binder, and the ligand-dimerizing agent binder conjugate comprises a ligand and a dimerizing agent binder.

2 . The recombinant nucleic acid of claim 1 , wherein the adenoviral capsid protein is operably linked to the dimerizing agent binder, the ligand is operably linked to the dimerizing agent binder, or both.

3 . The recombinant nucleic acid of claim 2 , wherein the adenoviral capsid protein is a fiber protein.

4 . The recombinant nucleic acid of claim 2 , wherein the ligand is capable of binding a tumor cell.

5 . The recombinant nucleic acid of claim 2 , wherein the ligand is an antibody.

6 . The recombinant nucleic acid of claim 5 , wherein the antibody is a single domain antibody.

7 . The recombinant nucleic acid of claim 1 , wherein the dimerizing agent binder of the capsid-dimerizing agent binder conjugate is a FRB protein.

8 . The recombinant nucleic acid of claim 1 , wherein the dimerizing agent binder of the ligand-dimerizing agent binder conjugate is an immunophilin protein.

9 . The recombinant nucleic acid of claim 8 , wherein the immunophilin protein is a FKBP protein.

10 . A recombinant adenovirus comprising the recombinant nucleic acid of claim 1 .

11 . A recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral capsid protein and a dimerizing agent binder.

12 . The recombinant adenovirus of claim 11 , wherein the capsid-dimerizing agent binder conjugate is bound to a dimerizing agent.

13 . The recombinant adenovirus of claim 12 , wherein the dimerizing agent is further bound to a ligand-dimerizing agent binder conjugate.

14 . The recombinant adenovirus of claim 12 , wherein the dimerizing agent is rapamycin.

15 . A cell comprising the recombinant adenovirus of claim 11 .

16 . A method of forming an adenoviral cancer cell targeting construct, comprising:

infecting a cell with the recombinant adenovirus of claim 10 , thereby forming an adenoviral infected cell;

allowing the adenoviral infected cell to express the recombinant nucleic acid, thereby forming a ligand-dimerizing agent binder conjugate and a recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate;

contacting the recombinant adenovirus and the ligand-dimerizing agent binder conjugate with a dimerizing agent; and

allowing the recombinant adenovirus and the ligand-dimerizing agent binder conjugate to bind to the dimerizing agent, thereby forming the adenoviral cancer cell targeting construct.

17 . A method of targeting a cell, comprising contacting a cell with a recombinant adenovirus of claim 11 .

18 . A method of targeting a cancer cell in a cancer patient, comprising:

administering to the cancer patient the recombinant adenovirus of claim 10 ;

allowing the recombinant adenovirus to infect a cell in the cancer patient, thereby forming an adenoviral infected cell;

allowing the adenoviral infected cell to express the recombinant nucleic acid, thereby forming a ligand-dimerizing agent binder conjugate and a recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate;

administering to the cancer patient a dimerizing agent;

allowing the recombinant adenovirus and the ligand-dimerizing agent binder conjugate to bind to the dimerizing agent, thereby forming an adenoviral cancer cell targeting construct; and

allowing the adenoviral cancer cell targeting construct to bind to a cancer cell, thereby targeting the cancer cell in the cancer patient.

19 . A method of targeting a cell, comprising:

contacting a first cell with the recombinant adenovirus of claim 10 ;

allowing the recombinant adenovirus to infect the first cell, thereby forming an adenoviral infected cell;

allowing the adenoviral infected cell to express the recombinant nucleic acid, thereby forming a ligand-dimerizing agent binder conjugate and a recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate;

contacting the ligand-dimerizing agent binder conjugate and the recombinant adenovirus with a dimerizing agent;

allowing the recombinant adenovirus and the ligand-dimerizing agent binder conjugate to bind to the dimerizing agent, thereby forming an adenoviral cell targeting construct; and

allowing the adenoviral cell targeting construct to bind to a second cell, thereby targeting the cell.

20 . The method of claim 19 , wherein the first cell and the second cell form part of an organism, or the first cell and the second cell form part of a tissue culture vessel.

Assignments (1)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →